Acute Lung Injury Clinical Trial
Official title:
Effects of Hyperoxia Induced Pulmonary Inflammation and Organ Injury in a Human in Vivo Model
Oxygen is the most commonly administered therapy in critical illness. Accumulating evidence suggests that patients often achieve supra-physiological levels of oxygenation in the critical care environment. Furthermore, hyperoxia related complications following cardiac arrest, myocardial infarction and stroke have also been reported. The underlying mechanisms of hyperoxia mediated injury remain poorly understood and there are currently no human in vivo studies exploring the relationship between hyperoxia and direct pulmonary injury and inflammation as well as distant organ injury. The current trial is a mechanistic study designed to evaluate the effects of prolonged administration of high-flow oxygen (hyperoxia) on pulmonary and systemic inflammation. The study is a randomised, double-blind, placebo-controlled trial of high-flow nasal oxygen therapy versus matching placebo (synthetic medical air). We will also incorporate a model of acute lung injury induced by inhaled endotoxin (LPS) in healthy human volunteers. Healthy volunteers will undergo bronchoalveolar lavage (BAL) at 6 hours post-intervention to enable measurement of pulmonary and systemic markers of inflammation, oxidative stress and cellular injury.
Status | Recruiting |
Enrollment | 53 |
Est. completion date | December 30, 2024 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: 1. Healthy non-smoking subjects less than 45 years of age and BMI < 29 kg/m² Exclusion Criteria: 1. Age < 18 years 2. On concomitant medications including over the counter medications excluding oral contraception and paracetamol 3. Previous adverse reactions to LPS, lignocaine or sedative agents 4. Pregnant or Breast-Feeding 5. Participation in a clinical trial of an investigational medicinal product within 30 days 6. Consent declined 7. History of asthma or other respiratory conditions 8. Smoking/ e cigarette use 9. Marijuana use or other inhaled products with or without nicotine in the last 3 months 10. Alcohol abuse, as defined by the Alcohol Use Disorders Identification Test (AUDIT) 11. Subjects with history of prior conventional cigarette (> 100 cigarettes lifetime and smoking within 6 months) or electronic cigarette use. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Belfast Health and Social Care Trus | Belfast |
Lead Sponsor | Collaborator |
---|---|
Belfast Health and Social Care Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bronchoalveolar lavage Interleukin-8 (IL-8) concentration | To determine the effects of hyperoxia on alveolar inflammatory response | 6 hours post-intervention | |
Secondary | Bronchoalveolar lavage cytokines including but not limited to tumour necrosis factor alpha, IL-1 beta and IL-6 | To determine the effects of hyperoxia on alveolar inflammatory response biomarkers | 6 hours post-intervention | |
Secondary | Bronchoalveolar lavage proteases and anti-proteases including but not limited to Matrix Metalloproteinases (MMP-2, MMP-8, MMP-9 and MMP-11), Tissue Inhibitors of Metalloproteinase (TIMPs 1-2) and neutrophil elastase | To determine the effects of hyperoxia on alveolar protease and antiprotease activity | 6 hours post-intervention | |
Secondary | Bronchoalveolar lavage white cell differential counts (total cell count, neutrophils, macrophages and lymphocytes) | To determine the effects of hyperoxia on alveolar cell populations | 6 hours post-intervention | |
Secondary | Plasma cytokines including but not limited to IL-8, tumour necrosis factor alpha, IL-1 beta and IL-6 | To determine the effects of hyperoxia on plasma inflammatory response biomarkers | 6 and 24 hours post-intervention | |
Secondary | Bronchoalveolar lavage soluble programmed cell death receptor (SP-D) | To determine the effects of hyperoxia on alveolar epithelial and endothelial function | 6 hours post-intervention | |
Secondary | Bronchoalveolar lavage total protein | To determine the effects of hyperoxia on alveolar epithelial and endothelial function | 6 hours post-intervention | |
Secondary | Bronchoalveolar lavage receptor for advanced glycation end-products (RAGE) | To determine the effects of hyperoxia on alveolar epithelial and endothelial function | 6 hours post-intervention | |
Secondary | Bronchoalveolar lavage 4-hydroxy-2-nonenal (4-HNE) | To determine the effects of hyperoxia on oxidative stress | 6 hours post-intervention | |
Secondary | Bronchoalveolar lavage oxidised low density lipoprotein (oxLDL) | To determine the effects of hyperoxia on oxidative stress | 6 hours post-intervention | |
Secondary | Plasma advanced glycation end products (AGE) | To determine the effects of hyperoxia on oxidative stress | 6 and 24 hours post-intervention | |
Secondary | Plasma oxidised low density lipoprotein (oxLDL) | To determine the effects of hyperoxia on oxidative stress | 6 and 24 hours post-intervention | |
Secondary | Plasma 4-hydroxy-2-nonenal (4-HNE) | To determine the effects of hyperoxia on oxidative stress | 6 and 24 hours post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03937947 -
Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
|
||
Completed |
NCT04247477 -
Comparison of Different PEEP Titration Strategies Using Electrical Impedance Tomography in Patients With ARDS
|
N/A | |
Completed |
NCT03315702 -
Effect of Mechanical Ventilation on Plasma Concentration Level of R-spondin Proteins
|
||
Not yet recruiting |
NCT02693912 -
Changes in Alveolar Macrophage Function During Acute Lung Injury
|
N/A | |
Completed |
NCT01659307 -
The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury
|
Phase 2 | |
Unknown status |
NCT01186874 -
Epidemiology Research on Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) in Adult ICU in Shanghai
|
N/A | |
Completed |
NCT01552070 -
Recruitment on Extravascular Lung Water in Acute Respiratory Distress Syndrome (ARDS)
|
Phase 2 | |
Withdrawn |
NCT00961168 -
Work of Breathing and Mechanical Ventilation in Acute Lung Injury
|
N/A | |
Recruiting |
NCT00759590 -
Comparison of Two Methods to Estimate the Lung Recruitment
|
N/A | |
Completed |
NCT00736892 -
Incidence of Acute Lung Injury: The Alien Study
|
||
Completed |
NCT02475694 -
Acute Lung Injury After Cardiac Surgery: Pathogenesis
|
N/A | |
Completed |
NCT00825357 -
Biological Markers to Identify Early Sepsis and Acute Lung Injury
|
N/A | |
Terminated |
NCT00263146 -
Recruitment Maneuvers in ARDS: Effects on Respiratory Function and Inflammatory Markers.
|
N/A | |
Completed |
NCT00188058 -
Comparison of 2 Strategies of Adjustment of Mechanical Ventilation in Patients With Acute Respiratory Distress Syndrome
|
N/A | |
Completed |
NCT00234767 -
Study of the Economics of Pulmonary Artery Catheter Use in Patients With Acute Respiratory Distress Syndrome (ARDS)
|
Phase 3 | |
Recruiting |
NCT02598648 -
Role and Molecular Mechanism of Farnesoid X Receptor(FXR) and RIPK3 in the Formation of Acute Respiratory Distress Syndrome in Neonates
|
N/A | |
Recruiting |
NCT02948530 -
Measurement of Lung Elastance and Transpulmonary Pressure Using Two Different Methods (Lungbarometry)
|
||
Completed |
NCT01532024 -
Exploratory Clinical Study of Neutrophil Activation Probe (NAP) for Optical Molecular Imaging in Human Lungs
|
Early Phase 1 | |
Recruiting |
NCT01992237 -
Measuring Energy Expenditure in ECMO (Extracorporeal Membrane Oxygenation) Patients
|
N/A | |
Completed |
NCT01486342 -
PET Imaging in Patients at Risk for Acute Lung Injury
|
N/A |